Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis

23 Sept 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Response and Inflammation
Share to Immune responses and vaccinations
Share to Tuberculosis Research and Epidemiology

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32978002
DOI: 10.1016/j.vaccine.2020.08.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosisPMID 32978002Read ↗

BCG Vaccines: Their mechanisms of attenuation and impact on safety and protective efficacySemantic proximity Read ↗

Infect and Inject: How Mycobacterium tuberculosis Exploits Its Major Virulence-Associated Type VII Secretion System, ESX-1Semantic proximity Read ↗

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB ProtectionSemantic proximity Read ↗

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics.Semantic proximity Read ↗

Improved Immune Responses and Tuberculosis Protection by Aerosol Vaccination with recombinant BCG expressing ESX-1 from <i>Mycobacterium marinum</i>Semantic proximity Read ↗

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trialsSemantic proximity Read ↗

BCG VaccinesSemantic proximity Read ↗

Mycobacterial EsxG·EsxH (TB9.8·TB10.4) peptides as a subunit vaccine to booster BCG vaccination in an experimental model of pulmonary TuberculosisSemantic proximity Read ↗

Genetic Modification of the BCG Vaccine to Overcome Its Limited Efficacy in Adults: A Specialized ReviewSemantic proximity Read ↗

Tuberculosis vaccines — an updateSemantic proximity Read ↗

Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspectiveSemantic proximity Read ↗

Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memorySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.